Portfolio concentration
As of January 31, 2026 · N-PORT
Holdings
63
Top-10 weight
49.29%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
22
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
489.2
Holdings
As of January 31, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | BlackRock Cash Funds: Institutional, SL Agency Shares | BISXX | 23,618,144 | $23.63M | 16.55% |
| 2 | MODERNA INC | — | 190,514 | $8.40M | 5.88% |
| 3 | Bayer Aktiengesellschaft | BAYN | 136,034 | $7.20M | 5.04% |
| 4 | REVOLUTION MEDICINES INC | — | 66,264 | $6.42M | 4.50% |
| 5 | TAKEDA PHARMACEU | — | 185,800 | $6.32M | 4.43% |
| 6 | BIONTECH SE ADR | — | 54,828 | $6.24M | 4.37% |
| 7 | ROCHE HOLDINGS AG (GENUSSCHEINE) | — | 13,651 | $6.21M | 4.35% |
| 8 | IPSEN | — | 37,167 | $6.07M | 4.25% |
| 9 | MERCK & CO | — | 52,921 | $5.84M | 4.09% |
| 10 | GSK PLC | — | 219,125 | $5.67M | 3.97% |
| 11 | REGENERON PHARMACEUTICALS INC | — | 7,346 | $5.45M | 3.81% |
| 12 | VERTEX PHARMACEUTICALS INC | — | 11,586 | $5.44M | 3.81% |
| 13 | GENMAB AS | — | 16,654 | $5.43M | 3.80% |
| 14 | INCYTE CORP | — | 51,475 | $5.15M | 3.61% |
| 15 | Sanofi SA | — | 53,301 | $5.03M | 3.52% |
| 16 | EXELIXIS INC | — | 118,964 | $4.92M | 3.45% |
| 17 | ARCELLX INC | — | 66,953 | $4.57M | 3.20% |
| 18 | IDEAYA BIOSCIENCES | — | 129,735 | $4.18M | 2.92% |
| 19 | CARIS LIFE SCIENCES INC | — | 178,559 | $4.14M | 2.90% |
| 20 | TWIST BIOSCIENCE CORP | — | 90,235 | $3.71M | 2.60% |
| 21 | IMMUNITYBIO INC | — | 513,330 | $3.21M | 2.25% |
| 22 | ONO PHARMA | — | 185,600 | $2.77M | 1.94% |
| 23 | ARCUS BIOSCIENCES INC | — | 115,988 | $2.44M | 1.71% |
| 24 | CRISPR Therapeutics A.G. Series A | CRSP US | 48,041 | $2.40M | 1.68% |
| 25 | NOVAVAX INC | — | 229,390 | $2.03M | 1.42% |
| 26 | NUVATION BIO INC | — | 370,402 | $1.94M | 1.36% |
| 27 | CORVUS PHARMACEUTICALS INC | — | 88,900 | $1.84M | 1.29% |
| 28 | IOVANCE BIOTHERAPEUTICS INC | — | 514,666 | $1.31M | 0.92% |
| 29 | AbCellera Biologics Inc COM | ABCL | 357,878 | $1.30M | 0.91% |
| 30 | GENFLEET THERAPEUTICS SHANGHAI INC | — | 300,800 | $1.18M | 0.83% |
| 31 | JANUX THERAPEUTICS INC | — | 83,115 | $1.14M | 0.80% |
| 32 | CYTOMX THERAPEUTICS INC | — | 198,426 | $1.13M | 0.79% |
| 33 | VIR BIOTECHNOLOGY INC | — | 144,941 | $1.08M | 0.76% |
| 34 | KURA ONCOLOGY INC | — | 130,406 | $1.06M | 0.74% |
| 35 | VALNEVA SE | — | 223,456 | $1.04M | 0.72% |
| 36 | ABCLON INC | — | 23,520 | $1.03M | 0.72% |
| 37 | RIGEL PHARMACEUTICALS INC | — | 27,421 | $955.90K | 0.67% |
| 38 | PACIFIC BIOSCIENES OF CALI INC | — | 417,556 | $943.68K | 0.66% |
| 39 | SUNSHINE LAKE PHARMA CO LTD | — | 165,900 | $904.24K | 0.63% |
| 40 | ALVOTECH SA | — | 163,916 | $880.23K | 0.62% |
| 41 | PERSONALIS INC | — | 82,376 | $771.86K | 0.54% |
| 42 | INTELLIA THERAPEUTICS INC | — | 57,945 | $761.98K | 0.53% |
| 43 | OCUGEN INC | — | 477,437 | $692.28K | 0.48% |
| 44 | VERASTEM INC | — | 100,510 | $613.11K | 0.43% |
| 45 | GINKGO BIOWORKS HOLDINGS INC | — | 65,516 | $587.68K | 0.41% |
| 46 | SHANGHAI HENLIUS BIOTECH INC H | 2696 | 73,000 | $535.66K | 0.38% |
| 47 | DESIGN THERAPEUTICS INC | — | 48,520 | $495.39K | 0.35% |
| 48 | XENCOR INC | — | 35,366 | $427.57K | 0.30% |
| 49 | GUANGZHOU INNOGEN PHARMACEUTICAL GROUP CO LTD | — | 104,600 | $399.01K | 0.28% |
| 50 | PRIME MEDICINE INC | — | 49,464 | $188.46K | 0.13% |
1 / 2
Next ›
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.